Fewer than a tenth of individuals who could benefit from weight-loss injections such as Wegovy have access to them, caution the World Health Organization as it releases its inaugural guidance on the medications.
With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is calling for more widespread and fairer availability to these injectable treatments.
Per forecasts, over two billion will be obese by 2030 without intervention.
"The new guidance acknowledges that excess weight is a lifelong illness that can be managed with thorough and ongoing support," said the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and supply-chain constraints are significant hurdles to broad access to the injections that can aid individuals in losing significant body mass, notes the organization.
Skinny Jab Shortage
Even in the present best projected outlook, the manufacturing of such drugs might only reach about 100 million people – less than 10% of the global need, according to the health organization.
The guideline urges nations and manufacturers to increase access, by approaches including licensing agreements.
Exclusive production rights on semaglutide – the main ingredient of the drug Wegovy – is set to lapse in a number of nations in 2026.
The Way Obesity Jabs Function
The injections mimick a body's own hormone to slow digestion, curb appetite and enhance the sense of being full so individuals consume fewer calories.
Patients commonly start to lose weight within a few weeks of starting on the once-weekly jabs.
Studies suggests patients may see weight return within a year of halting the drug, because their typical appetite come back.
To be carrying excess weight increases your likelihood for experiencing health problems, including type 2 diabetes, heart disease, brain attack, and specific malignancies.
Obesity affects people in every country and was associated with 3.7 million deaths worldwide in 2024, per the WHO.
